Albendazole
Treatment for Ascariasis
Typical Dosage: 400 mg oral single dose
Effectiveness
95%
Safety Score
70%
Clinical Trials
8
Participants
2M
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
400 mg oral single dose
Time to Effect
1-3 days
Treatment Duration
Single dose
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10
Monitoring:$600
Side Effect Mgmt:$0
Total Annual:$610
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
0.05
Outcome-Based Costs
Cost per Responder
$10.2
Cost per Remission
$10.53
Prescription Access Economics
Annual Societal Loss per Patient
$110
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$150/year
Time Cost
$35/year
Travel + wait time
Insurance Admin Cost
$20/year
Prior auth, claims
Rx Price
$10/year
Potential OTC Price
$5/year
Estimated if OTC available
Early Treatment Benefit
+0.01 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWAlbendazole Outcomes
for Ascariasis
Efficacy Outcomes
Overall Effectiveness
+95%
Response Rate
+98%
Remission Rate
+95%
Common Side Effects
Abdominal pain
+10%
Nausea/Vomiting
+8%
Headache
+5%
Dizziness
+3%
Sources:
Active Clinical Trials
2 active trials recruiting for Albendazole in Ascariasis
Follow-up Assessment of Change in Soil-transmitted Helminths Infection Intensity in Uganda
NCT07873398NOT YET RECRUITINGPHASE3
450 participants
INTERVENTIONAL
Kampala, Uganda
Started: Oct 1, 2026
Combination Therapies for Trichuris Trichiura Infection in Schoolchildren in Honduras
NCT07661316NOT YET RECRUITINGPHASE3
368 participants
INTERVENTIONAL
Tegucigalpa, Honduras
Started: Nov 1, 2026
Completed Clinical Trials
7 completed trials for Albendazole in Ascariasis
Efficacy Albendazole and Levamisole Against STH on Unguja
NCT00659997COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Stone Town, Tanzania
Started: Jun 1, 2006
Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC
NCT06188715COMPLETEDPHASE3
224 participants
INTERVENTIONAL
Chake Chake, Tanzania
Started: May 14, 2024
Efficacy and Safety of MOX/ALB Co-administration
NCT04726969COMPLETEDPHASE3
255 participants
INTERVENTIONAL
Abidjan, Côte d’Ivoire
Started: Jun 15, 2021
Impact of Repeated Anthelmintic Treatment on the Risk of Malaria in Kenyan School Children
NCT01658774COMPLETEDNA
2.38K participants
INTERVENTIONAL
Nairobi, Kenya
Started: Jan 1, 2013
Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections
NCT00207753COMPLETEDNA
550 participants
INTERVENTIONAL
Poptún, Guatemala
Started: Feb 1, 2005
Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC
NCT06184399COMPLETEDPHASE2
260 participants
INTERVENTIONAL
Chake Chake, Tanzania
Started: Jun 5, 2024
Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration
NCT04700423COMPLETEDPHASE2, PHASE3
536 participants
INTERVENTIONAL
Chake Chake, Tanzania
Started: Mar 1, 2021